武田2016财年年报及2017财年目标

2017年5月10日 China
  • 得益于盈利增长 ,2016财年业绩超出目标
  • 基础业绩: 营收增长+6.9%,核心盈余增长+24.2%,核心每股收益增长+20.9%
  • 武田预估2017财年盈利继续增长

与去年同期相比实现了持续性利润增长

  • 基础营收增长6.9%,其中武田利润增长引擎(消化治疗领域,肿瘤治疗领域,中枢神经系统治疗领域和新兴市场)贡献了14.7%的增长,所有地区的基础营收分别为:美国增长了 12.8%,日本增长了5.0%,欧洲和加拿大增长了4.7%,新兴市场增长了 4.5%。 由于受埃及等地区货币贬值(-6.6pp)和资产剥离的影响(-4.5pp),财报总营收下降了4.2%。
  • 同期基础核心盈利增长了24.2%,核心盈利率上升了180个基点。尽管有货币贬值和资产剥离的负面影响,但是强劲的基础营收增长以及和Teva合资企业的一次性交易收益,使我们运营利润仍然保持增长了19.1%的好势头。
  • 同期对比核心每股盈利增长20.9%,反映了强劲的核心盈利增长力。今年每股盈利为147日元,比上年的102日元同期增长近 43.9%。
  • 调整后的运营现金流量为1588亿日元,高于下一年的股利支付。

武田利润增长动力保持了14.7%的增长

  • ENTYVIO® and TAKECAB®带动消化治疗领域总营收增长了33.5%。
  • 得益于NINLARO® and ADCETRIS®,肿瘤治疗领域总营收增长了7.5%。
  • 中枢神经系统治疗领域总营收上升了26.7%,TRINTELLIX®上市后的强劲表现至关重要。
  • 新兴市场总营收增长4.5%,其中主要市场,如中国,俄罗斯和巴西都起到了积极作用。

武田总裁兼首席执行官Christophe Weber说

 “我们在2016财年的取得的不俗业绩突显了武田战略转型的成功。

我们的增长动力保持强劲势头,通过收益增长和管理运营成本管理,大大提高了利润增长。我相信武田将在发展中期继续实现利润和利润率的增长,随着我们继续执行战略转型,武田将有强大的动力保持长期的增长。”

Reported Results for FY2016 (April – March)

(billion yen)

FY2015

FY2016

Growth

Reported

 

Revenue

1,807.4

1,732.1

-4.2%

Revenue

Core Earnings1

292.0

245.1

-16.0%

Core Earnings1

Operating Profit

130.8

155.9

+19.1%

Operating Profit

Net Profit3

80.2

114.9

+43.4%

Net Profit3

EPS

102 yen

147 yen

+43.9%

EPS

Core EPS

255 yen

220 yen

-13.6%

Core EPS

1    Core Earnings is calculated by taking reported Gross Profit and deducting SG&A expenses and R&D expenses. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.

2    Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures from both periods.

3    Attributable to the owners of the company.

FY2017 Management Guidance:
Takeda will boost margins and drive continued profitable growth

 

Guidance (growth %)

Underlying Revenue

Low single digit

Underlying Core Earnings

Mid-to-high teen

Underlying Core EPS

Low-to-mid teen

Annual dividend per share

180 yen



FY2017 Reported Forecast:
Reported EPS in FY2017 is forecast to increase 20% to 177 yen per share

(billion yen)

FY2016 Results

FY2017 Forecast

% change

Revenue

1,732.1

1,680.0

-3.0%

Operating Profit

155.9

180.0

+15.5%

Net Profit

114.9

138.0

+20.1%

EPS

147 yen

177 yen

+20.1%

Exchange Rate
(annual average)

1 US$= 109 yen

1 euro= 120 yen

1 US$= 110 yen

1 euro= 120 yen

 

For more details on Takeda’s FY2016 results and other financial information please visit https://www.takeda.com/investors/reports/